FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lux Biosciences will have to do another clinical trial - on top of three already completed Phase III studies - for FDA to consider approving its uveitis treatment Luveniq (voclosporin), the agency said in a "complete response" letter announced Aug. 4
You may also be interested in...
Hot Spaces Track To Offer Broad Array Of Late-Stage Partnering Opportunities
Without a therapeutic category to narrow down all the options, Catherine Staughton faced quite a challenge in pulling together the 10 product candidates that comprise the Hot Spaces track at this year’s Windhover Therapeutic Areas Partnership conference.
Hot Spaces Track To Offer Broad Array Of Late-Stage Partnering Opportunities
Without a therapeutic category to narrow down all the options, Catherine Staughton faced quite a challenge in pulling together the 10 product candidates that comprise the Hot Spaces track at this year’s Windhover Therapeutic Areas Partnership conference.
Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt
"Several outstanding issues" forced FDA to cancel the meeting, the agency said.